Properties (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Dainippon_Pharmaceutical
|
| gptkbp:awards |
various industry awards
|
| gptkbp:CEO |
gptkb:Masayo_Tada
|
| gptkbp:clinicalTrials |
Phase IV
ongoing Phase II Phase III Phase I integrated approach conducted globally |
| gptkbp:collaborations |
international pharmaceutical companies
|
| gptkbp:communityInvolvement |
yes
|
| gptkbp:corporateSocialResponsibility |
active
|
| gptkbp:culturalHeritage |
inclusive
|
| gptkbp:employees |
approximately 7,000
comprehensive |
| gptkbp:firstDeployment |
diverse
|
| gptkbp:focusArea |
research and development
|
| gptkbp:founded |
2005
|
| gptkbp:globalPresence |
yes
|
| gptkbp:headCoach |
Dr._Hiroshi_Takeda
|
| gptkbp:headquarters |
gptkb:Osaka,_Japan
|
| gptkbp:historicalResearch |
yes
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sumitomo Dainippon Pharma
|
| gptkbp:innovation |
focus on innovative therapies
|
| gptkbp:investmentFocus |
medical devices
biopharmaceuticals digital health |
| gptkbp:market |
global
|
| gptkbp:marketSegment |
diversification
global expansion |
| gptkbp:netIncome |
approximately $300 million
|
| gptkbp:parentCompany |
gptkb:Sumitomo_Group
|
| gptkbp:partnerships |
biotechnology companies
strategic partnerships various academic institutions |
| gptkbp:patentCitation |
numerous
|
| gptkbp:products |
antidepressants
antipsychotics oncology drugs |
| gptkbp:research_areas |
yes
neurology oncology psychiatry |
| gptkbp:researchAndDevelopment |
approximately 20% of revenue
|
| gptkbp:researchFocus |
oncology
central nervous system disorders |
| gptkbp:revenue |
approximately $2 billion
|
| gptkbp:stockExchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:stockSymbol |
4506
|
| gptkbp:subsidiary |
Sumitomo Pharma USA, Inc.
Sumitomo_Pharma_Canada_Ltd. Sumitomo_Pharma_Europe_Ltd. |
| gptkbp:sustainabilityInitiatives |
yes
|
| gptkbp:training |
ongoing
|
| gptkbp:website |
www.sumitomodainipponpharma.com
|